Division of Cardiology, Advocate Children's Hospital, Oak Lawn, IL.
Department of Pediatrics, Chicago Medical School/Rosalind Franklin University of Medicine and Science, North Chicago, IL.
Am J Ther. 2024;31(5):e531-e540. doi: 10.1097/MJT.0000000000001711.
In pediatric critical care, vasoactive/inotropic support is widely used in patients with heart failure, but it remains controversial because the influence of multiple medications and the interplay between their inotropic and vasoactive effects on a given patient are hard to predict. Robust evidence supporting their use and quantifying their effects in this group of patients is scarce.
The aim of this study was to characterize the effect of vasoactive medications on various cardiovascular parameters in pediatric patient with decreased ejection fraction.
Clinical-data based physiologic simulator study.
We used a physics-based computer simulator for quantifying the response of cardiovascular parameters to the administration of various types of vasoactive/inotropic medications in pediatric patients with decreased ejection fraction. The simulator allowed us to study the impact of increasing medication dosage and the simultaneous administration of some vasoactive agents. Correlation and linear regression analyses yielded the quantified effects on the vasoactive/inotropic support.
Cardiac output and systemic venous saturation significantly increased with the administration of dobutamine and milrinone in isolation, and combination of milrinone with dobutamine, dopamine, or epinephrine. Both parameters decreased with the administration of epinephrine and norepinephrine in isolation. No significant change in these hemodynamic parameters was observed with the administration of dopamine in isolation.
Milrinone and dobutamine were the only vasoactive medications that, when used in isolation, improved systemic oxygen delivery. Milrinone in combination with dobutamine, dopamine, or epinephrine also increased systemic oxygen delivery. The induced increment on afterload can negatively affect systemic oxygen delivery.
在儿科重症监护中,血管活性/正性肌力支持广泛应用于心力衰竭患者,但由于多种药物的影响以及它们的正性肌力和血管活性作用对特定患者的相互作用难以预测,因此其应用仍存在争议。支持其使用并量化其在这群患者中的效果的有力证据很少。
本研究旨在描述血管活性药物对射血分数降低的儿科患者各种心血管参数的影响。
基于临床数据的生理模拟器研究。
我们使用基于物理的计算机模拟器来量化各种类型的血管活性/正性肌力药物在射血分数降低的儿科患者中对心血管参数的反应。该模拟器使我们能够研究增加药物剂量和同时给予一些血管活性药物的影响。相关和线性回归分析得出了量化的血管活性/正性肌力支持的效果。
单独给予多巴酚丁胺和米力农、米力农与多巴酚丁胺、多巴胺或肾上腺素联合使用时,心输出量和全身静脉血氧饱和度显著增加。单独给予肾上腺素和去甲肾上腺素时,这两个参数均下降。单独给予多巴胺时,这些血液动力学参数没有明显变化。
米力农和多巴酚丁胺是唯一两种单独使用时可改善全身氧输送的血管活性药物。米力农与多巴酚丁胺、多巴胺或肾上腺素联合使用也可增加全身氧输送。后负荷的增加会对全身氧输送产生负面影响。